Last reviewed · How we verify
Other PPI marketed in Sweden
Proton pump inhibitors (PPIs) block the hydrogen/potassium ATPase pump in gastric parietal cells, reducing gastric acid secretion.
Proton pump inhibitors (PPIs) block gastric acid secretion by irreversibly inhibiting the H+/K+-ATPase enzyme in parietal cells of the stomach. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Other PPI marketed in Sweden |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
PPIs are prodrugs that are activated in the acidic environment of the parietal cell canaliculus and irreversibly inhibit the H+/K+-ATPase pump, the final step of gastric acid secretion. This results in profound and long-lasting suppression of both basal and stimulated gastric acid production, providing relief from acid-related gastrointestinal conditions.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Abdominal pain
- Nausea
- Constipation
- Hypomagnesemia (with long-term use)
- Vitamin B12 deficiency (with long-term use)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Other PPI marketed in Sweden CI brief — competitive landscape report
- Other PPI marketed in Sweden updates RSS · CI watch RSS
- AstraZeneca portfolio CI